(“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan. “We enter ...
NASA had a plan but it got "out of control," in the words ... In order to maximize the chance of the sample return mission moving forward, NASA chose not one but two options to pursue.